Mycobacterium Bovis Sternoclavicular Joint Septic Arthritis in Patient on Avelumab for Metastatic Urothelial Cell Carcinoma

Author(s): Karim Germanos, Changsu L. Park, Ramy R. Saleh, Feras A. Moria

Bladder cancer is the sixth most common cancer worldwide intravesical BCG has been the standard of care of treating non-muscle-invasive bladder cancer (NMIBC) following TURBT since late 70s and early 80s. Despite of is efficacy and safety it has been associated with non-negligible risk of recurrence and about 1-5% risk of infectious complications. The current recommendation for treatment of advanced urothelial cancer (aUC) is combined platinum doublets followed by maintenance avelumab in patient who didn’t progress on chemotherapy. We report a case of a 69-year-old male with aUC who progressed following adjuvant intravesical therapy and subsequently developed right sternoclavicular joint (SCJ) septic arthritis 16 months following finishing BCG treatment and while receiving immunotherapy.